BONEFOS
BAYER
Identification
- Active ingredient (INN)
- CLODRONATE DISODIQUE TETRAHYDRATE
- Internal code
- 05 F 153
- Country of Origin
- Finland
- Pharmaceutical form
- Film-coated Tablet
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/100
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Strengthen the bones and prevent their breaking and damaging.
Reduce the high levels of calcium among breast cancer patients, which spread to the bones or multiple pure cancer patients.
Associated Conditions
The following cases are used with caution under the supervision of the doctor: heart disease and hypertension.
Unsystematic levels of potassium and magnesium in blood.
During breastfeeding and pregnancy, there are insufficient studies on safety of use.
Dental problems such as gum disease, use of dental sets, tooth castle, oral surgery and smoking.
The patient must therefore examine the teeth before starting treatment with this drug.
The use of pyphosphonysis leads to a condition called jaw vaporism, the opportunity for this condition increases in the event of oral dishygiesis.
Mechanism of Action
It is used in hypercalcium cases, where it prevents bone metabolism or bone reversibility, where these substances are closely associated with bone tissues and prevents calcium loss through bone-breaking cells, and also protects these cells from breaking and breaking bone.
Do you have questions related to this? Ask Sina, artificial intelligence to answer all your medical questions.